Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | HAAO | P46952 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4748789 | 0.83 | KDM4E (0.37) | MAPTALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL5593255 | 0.80 | TDP1 (0.41) | TDP1MAPTALDH1A1HSD17B10POLB | |
| SCHEMBL6646160 | 0.78 | TDP1 (0.52) | TDP1MAPTALDH1A1HSD17B10KDM4E | |
| SCHEMBL28363838 | 0.78 | CYP1A2 (0.52) | MAPTALDH1A1KDM4EHPGDNOTUM | |
| SCHEMBL4696826 | 0.77 | KDM4E (0.48) | ALDH1A1HSD17B10KDM4EHPGDNOTUM | |
| SCHEMBL11218412 | 0.77 | TDP1 (0.50) | TDP1MAPTALDH1A1HSD17B10KDM4E | |
| SCHEMBL400759 | 0.76 | NOTUM (0.43) | MAPTNOTUMHAAO | |
| SCHEMBL3107355 | 0.75 | NOTUM (0.40) | ALDH1A1HSD17B10KDM4EHPGDNOTUM | |
| SCHEMBL17371291 | 0.75 | TDP1 (0.68) | TDP1MAPTALDH1A1HSD17B10KDM4E | |
| SCHEMBL2383155 | 0.74 | ALDH1A1 (0.42) | ALDH1A1HSD17B10KDM4EHPGDNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357809-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-7915410-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-20070082909-A1 | Acyclic Ikur inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082909-A1 | Acyclic Ikur inhibitors | KCNH2, KCNJ2, KCNH3 | TDP1 1997/4885MAPT 4688/4885ALDH1A1 1792/4885 |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | KCNH2, KCNJ2, KCNH3 | TDP1 1997/4885MAPT 4688/4885ALDH1A1 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.